FDA extends comment time on rule for US imports:
This article was originally published in Clinica
The FDA has reopened the comment period for a further 60 days on its proposed rule requiring foreign establishments whose food, drug and device products are imported into the US to register with the FDA. The Canadian government said the proposed requirement could present significant cost and compliance burdens to its small and medium-sized companies so it needed more time to prepare comments and ensure that its firms are aware of the proposal. The comment period initially ended on July 28 it will now close on October 8.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.